← Back to patent-cliff list

Alvelestat

Tier C — Watch / trade

Alvelestat

AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:ELANE

Indications (approved):COVID-19, α1抗胰蛋白酶缺乏症, Emphysema, Chronic obstructive pulmonary disease, 闭塞性细支气管炎, Graft-versus-host disease, Type 2 diabetes, Insulin resistance

Regional status

US
Phase II
2009-07-01
EU
Phase II
2008-06-01
China
-
Japan
No progress
2009-07-01

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield 96 kg
ALVEL-00198-16-8ALVEL-002—ALVEL-00315386-86-4ALVEL-0044652-27-1ALVEL-005694479-56-6ALVEL-006950857-36-0ALVEL-007847818-74-0ALVEL-008848141-07-1ALVEL-009848141-14-0ALVEL-01097483-77-7ALVEL-011848141-13-9Alvelestat848141-11-7API · Alvelestat
CodeCAS No.Intermediate
ALVEL-00198-16-83-(trifluoromethyl)aniline
ALVEL-002-ethyl 3-chloro-3-oxopropanoate
ALVEL-00315386-86-4ethyl 3-oxo-3-[3-(trifluoromethyl)anilino]propanoate
ALVEL-0044652-27-1ethyl 3-oxo-3-((3-(trifluoromethyl)phenyl)amino)propanoate
ALVEL-005694479-56-6(E)-4-methoxybut-3-en-2-one
ALVEL-006950857-36-06-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxylic acid
ALVEL-007847818-74-01-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
ALVEL-008848141-07-16-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxylic acid
ALVEL-009848141-14-06-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxylic acid
ALVEL-01097483-77-7(5-(methylsulfonyl)pyridin-2-yl)methanamine hydrochloride
ALVEL-011848141-13-95-bromopicolinonitrile
Alvelestat848141-11-75-(methylsulfonyl)picolinonitrile

Frequently asked questions

What are the approved indications of Alvelestat?

Approved indications include: COVID-19, α1抗胰蛋白酶缺乏症, Emphysema, Chronic obstructive pulmonary disease, 闭塞性细支气管炎, Graft-versus-host disease, Type 2 diabetes, Insulin resistance.

When does the Alvelestat patent expire?

No public expiry year is available for Alvelestat yet; this page updates once verified.

How many synthesis routes are recorded for Alvelestat?

1 synthesis routes are recorded; the shortest is 7 steps with 96 kg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Alvelestat intermediates?

All intermediates in Alvelestat routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Alvelestat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-22